IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-45723-z.html
   My bibliography  Save this article

Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer

Author

Listed:
  • Nandini Pal Basak

    (Farcast Biosciences India Pvt. Ltd)

  • Kowshik Jaganathan

    (Farcast Biosciences India Pvt. Ltd)

  • Biswajit Das

    (Farcast Biosciences India Pvt. Ltd)

  • Oliyarasi Muthusamy

    (Farcast Biosciences India Pvt. Ltd)

  • Rajashekar M

    (Farcast Biosciences India Pvt. Ltd)

  • Ritu Malhotra

    (Farcast Biosciences India Pvt. Ltd)

  • Amit Samal

    (Farcast Biosciences India Pvt. Ltd)

  • Moumita Nath

    (Farcast Biosciences India Pvt. Ltd)

  • Ganesh MS

    (Vydehi Institute of Medical Sciences & Research Centre)

  • Amritha Prabha Shankar

    (Vydehi Institute of Medical Sciences & Research Centre)

  • Prakash BV

    (Sri Lakshmi Multi-Speciality Hospital)

  • Vijay Pillai

    (Mazumdar Shaw Medical Center, Narayana Health)

  • Manjula BV

    (Bangalore Baptist Hospital)

  • Jayaprakash C

    (DBR & SK Super Speciality Hospital)

  • Vasanth K

    (Farcast Biosciences India Pvt. Ltd)

  • Gowri Shankar K

    (Farcast Biosciences India Pvt. Ltd)

  • Sindhu Govindan

    (Farcast Biosciences India Pvt. Ltd)

  • Syamkumar V

    (Farcast Biosciences India Pvt. Ltd)

  • Juby

    (Farcast Biosciences India Pvt. Ltd)

  • Koushika R

    (Farcast Biosciences India Pvt. Ltd)

  • Chandan Bhowal

    (Farcast Biosciences India Pvt. Ltd)

  • Upendra Kumar

    (Farcast Biosciences India Pvt. Ltd)

  • Govindaraj K

    (Farcast Biosciences India Pvt. Ltd)

  • Mohit Malhotra

    (Farcast Biosciences India Pvt. Ltd)

  • Satish Sankaran

    (Farcast Biosciences India Pvt. Ltd)

Abstract

Dynamic interactions within the tumor micro-environment drive patient response to immune checkpoint inhibitors. Existing preclinical models lack true representation of this complexity. Using a Head and Neck cancer patient derived TruTumor histoculture platform, the response spectrum of 70 patients to anti-PD1 treatment is investigated in this study. With a subset of 55 patient samples, multiple assays to characterize T-cell reinvigoration and tumor cytotoxicity are performed. Based on levels of these two response parameters, patients are stratified into five sub-cohorts, with the best responder and non-responder sub-cohorts falling at extreme ends of the spectrum. The responder sub-cohort exhibits high T-cell reinvigoration, high tumor cytotoxicity with T-cells homing into the tumor upon treatment whereas immune suppression and tumor progression pathways are pre-dominant in the non-responders. Some moderate responders benefit from combination of anti-CTLA4 with anti-PD1, which is evident from better cytotoxic T-cell: T-regulatory cell ratio and enhancement of tumor cytotoxicity. Baseline and on-treatment gene expression signatures from this study stratify responders and non-responders in unrelated clinical datasets.

Suggested Citation

  • Nandini Pal Basak & Kowshik Jaganathan & Biswajit Das & Oliyarasi Muthusamy & Rajashekar M & Ritu Malhotra & Amit Samal & Moumita Nath & Ganesh MS & Amritha Prabha Shankar & Prakash BV & Vijay Pillai , 2024. "Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45723-z
    DOI: 10.1038/s41467-024-45723-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-45723-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-45723-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Chia-Chin Wu & Y. Alan Wang & J. Andrew Livingston & Jianhua Zhang & P. Andrew Futreal, 2022. "Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    2. Dora Hammerl & John W. M. Martens & Mieke Timmermans & Marcel Smid & Anita M. Trapman-Jansen & Renée Foekens & Olga I. Isaeva & Leonie Voorwerk & Hayri E. Balcioglu & Rebecca Wijers & Iris Nederlof & , 2021. "Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    3. Susan P. Foy & Kyle Jacoby & Daniela A. Bota & Theresa Hunter & Zheng Pan & Eric Stawiski & Yan Ma & William Lu & Songming Peng & Clifford L. Wang & Benjamin Yuen & Olivier Dalmas & Katharine Heeringa, 2023. "Non-viral precision T cell receptor replacement for personalized cell therapy," Nature, Nature, vol. 615(7953), pages 687-696, March.
    4. Caroline Robert, 2020. "A decade of immune-checkpoint inhibitors in cancer therapy," Nature Communications, Nature, vol. 11(1), pages 1-3, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Qianqian Ming & Daniel Antfolk & David A. Price & Anna Manturova & Elliot Medina & Srishti Singh & Charlotte Mason & Timothy H. Tran & Keiran S. M. Smalley & Daisy W. Leung & Vincent C. Luca, 2024. "Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    2. Yue Wang & Shi-Kun Zhou & Yan Wang & Zi-Dong Lu & Yue Zhang & Cong-Fei Xu & Jun Wang, 2023. "Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    3. Avishai Maliah & Nadine Santana-Magal & Shivang Parikh & Sagi Gordon & Keren Reshef & Yuval Sade & Aseel Khateeb & Alon Richter & Amit Gutwillig & Roma Parikh & Tamar Golan & Matan Krissi & Manho Na &, 2024. "Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    4. Mingming Zhao & Xiaohui Cheng & Pingwen Shao & Yao Dong & Yongjie Wu & Lin Xiao & Zhiying Cui & Xuedi Sun & Chuancheng Gao & Jiangning Chen & Zhen Huang & Junfeng Zhang, 2024. "Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    5. Derin Sevenler & Mehmet Toner, 2024. "High throughput intracellular delivery by viscoelastic mechanoporation," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    6. Weiyue Zheng & Wanda Marini & Kiichi Murakami & Valentin Sotov & Marcus Butler & Chiara Gorrini & Pamela S. Ohashi & Michael Reedijk, 2024. "Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    7. Caihua Zhang & Kang Li & Hongzhang Zhu & Maosheng Cheng & Shuang Chen & Rongsong Ling & Cheng Wang & Demeng Chen, 2024. "ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    8. Pooja Middha & Rohit Thummalapalli & Michael J. Betti & Lydia Yao & Zoe Quandt & Karmugi Balaratnam & Cosmin A. Bejan & Eduardo Cardenas & Christina J. Falcon & David M. Faleck & Matthew A. Gubens & S, 2024. "Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    9. Jianting Long & Xihe Chen & Mian He & Shudan Ou & Yunhe Zhao & Qingjia Yan & Minjun Ma & Jingyu Chen & Xuping Qin & Xiangjun Zhou & Junjun Chu & Yanyan Han, 2024. "HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice," Nature Communications, Nature, vol. 15(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45723-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.